XLV (Health Care Select Sector SPDR) is a market-cap-weighted ETF designed to reflect the health care sector within the S&P 500, so its day-to-day moves are dominated by a handful of mega-cap constituents rather than smaller biotech. Recent fund materials and third-party summaries highlight that its biggest influences typically include Eli Lilly, Johnson & Johnson, AbbVie, and UnitedHealth, meaning pharma/biopharma and managed care often explain most of the ETF’s direction on modest-move days. (kiplinger.com)

There does not appear to be a single, clean ETF-specific headline causing a -0.35% move; instead, the tape looks like sector-level chop during earnings season and ongoing investor positioning across defensives versus growth. Broader market commentary for April 24, 2026 describes dispersion/rotation rather than one macro shock, and healthcare specifically showing a split where managed care strength can be offset by weakness elsewhere in the group—consistent with a small ETF decline without a dominant catalyst. (monexa.ai)

Earnings setup: Health-care earnings expectations have been pressured versus other sectors, increasing sensitivity to company-by-company results and guidance as reports approach, which can keep XLV choppy even on quiet macro days. (schwab.com) Managed-care policy/rates: Medicare Advantage rate decisions and company responses remain a major swing factor for XLV’s insurer exposure; recent developments around Medicare rates have driven notable moves in managed-care names, which can either cushion or drag the ETF depending on the day’s direction. (schaeffersresearch.com) Mega-cap concentration: Because XLV is cap-weighted, even modest moves in its largest pharma/biopharma holdings can outweigh strength in smaller subsectors—so investors should watch the top weights first when XLV moves a few tenths of a percent. (ssga.com)

For the next clear catalyst, focus on (a) upcoming large-cap healthcare earnings and guidance and (b) any incremental Medicare Advantage reimbursement or utilization commentary from insurers. If rates move sharply, expect a secondary effect through style/positioning: defensives can outperform on risk-off days, but XLV can still fall if its concentrated mega-cap holdings are the ones being sold.